N2OFF, Inc. (NITO) 股票分析

公司概述

N2OFF, Inc. operates as an agri-food technology entity focused on the development and commercialization of eco-friendly green solutions designed to enhance food safety and extend the shelf life of fresh produce within the food industry. The company functions within the Basic Materials sector, specifically the Agricultural Inputs industry, positioning itself to address supply chain sustainability and preservation challenges. With a market capitalization of $2.52M and an annual revenue of $209,000 over the trailing twelve months, the firm maintains a lean operational structure supported by only three employees. These financial figures indicate a micro-cap status where the company's revenue base is extremely limited relative to its market cap, suggesting a valuation that does not yet reflect significant current operational scale but rather potential future development phases.

财务健康

The company reported a revenue of $209,000 for the trailing twelve months, yet it recorded a net income of $-6,942,000 and an EBITDA of $-6,024,000, revealing a severe disconnect where costs far exceed income generation. The substantial gap between the modest revenue and the massive negative net income indicates a highly volatile cost structure, likely driven by significant one-time expenses or heavy investment in research and development that has not yet been amortized against current sales. Free cash flow stands at $-3,829,648, which signifies that the company is burning cash rapidly and lacks immediate financial flexibility to fund operations without external capital injections. Margin analysis shows a gross margin of 64.6%, suggesting efficient production costs relative to sales, but this is overwhelmed by an operating margin of -66,300.0% and a profit margin of 0.0%, highlighting that overhead and other expenses are disproportionately high compared to revenue. On the balance sheet, the company holds $6.28M in cash against $1.14M in debt, resulting in a debt-to-equity ratio of 13.08, which technically indicates a leveraged position despite the cash buffer, as the equity base is likely negative or negligible given the losses. The current ratio of 4.21 suggests strong short-term liquidity in terms of asset coverage, yet this metric can be misleading when a significant portion of current assets is tied up in cash while the company remains unprofitable. Return on Equity is -101.6% and Return on Assets is -44.8%, metrics that reveal management has been ineffective at generating positive returns from the capital deployed, as the company continues to erode shareholder value and asset worth.

估值评估

Trailing P/E and forward P/E are both listed as N/A due to the company's lack of net income, which implies that traditional earnings-based valuation models are currently inapplicable and that future earnings trajectory remains highly uncertain. The price-to-book ratio is 0.14, indicating that the market values the company at a fraction of its book value, a common characteristic for distressed or early-stage biotech and tech firms where intangible assets or future potential outweigh reported historical book value. Alternative valuation metrics include a price-to-sales ratio of 12.07 and an EV/EBITDA of 0.48, suggesting that the market is pricing the stock based on revenue potential rather than profitability, though the high P/S multiple relative to such low revenue implies significant growth expectations or speculative positioning. The stock has traded between a 52-week high of $29.40 and a 52-week low of $0.77, and without a specific current price provided in the facts, the valuation context relies on these extremes to show the wide volatility range inherent in the security. The beta value of 1.64 indicates that the stock is significantly more volatile than the broader market, moving with 64% greater amplitude than the market index, which amplifies both potential upside and downside risk for holders.

Growth & Income

Revenue growth year-over-year is -77.8%, while earnings growth is N/A due to the negative earnings history, implying that the company is currently in a contraction phase regarding top-line sales rather than a growth phase. Since the company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it does not return cash to shareholders but instead retains earnings—however negative they are—to fund its operations and proprietary development. The absence of a payout ratio means the company is not distributing income, effectively reinvesting its limited resources into its agri-food technology initiatives rather than providing income to investors. The overall growth and income profile is characterized by negative revenue expansion and a complete lack of dividend income, presenting a high-risk, high-volatility investment scenario where capital preservation is difficult given the substantial cash burn and negative growth rates.